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Clinical PerspectiveWhat Is New?A molecular genetic cause of long‐QT syndrome was detected in 6.5% of patients with at least 1 ECG with a corrected QT interval ≥500 ms.In most patients with a pathogenic or likely pathogenic variant, the prolonged corrected QT interval had not been acknowledged in the medical records.What Are the Clinical Implications?We recommend increased awareness of the possibility of congenital long‐QT syndrome in patients with at least 1 ECG with a corrected QT interval ≥500 ms.

Introduction {#jah33422-sec-0008}
============

Congenital long‐QT syndrome (LQTS) is a genetic disorder characterized by prolongation of the corrected QT interval (QTc) on an ECG. It is associated with increased risk of torsade de pointes ventricular tachycardia and sudden cardiac death. The estimated prevalence of LQTS is 1:2000 live births.[1](#jah33422-bib-0001){ref-type="ref"}

QTc ≥500 ms is considered to be highly abnormal and associated with increased risk of torsade de pointes ventricular tachycardia,[2](#jah33422-bib-0002){ref-type="ref"} but also carriers of LQTS mutations with a QTc ≤440 ms have an increased risk of life‐threatening cardiac events.[3](#jah33422-bib-0003){ref-type="ref"} Treatment with β‐blocker medication significantly reduces the risk of adverse outcomes.[4](#jah33422-bib-0004){ref-type="ref"}

More than 1500 sequence variants in 17 genes have previously been reported to be pathogenic or likely pathogenic for LQTS, although the evidence for some of these is limited.[5](#jah33422-bib-0005){ref-type="ref"} Autosomal dominant is the most common inheritance pattern, and *KCNQ1* (LQT1) harbors most genetic defects, followed by *KCNH2* (LQT2) and *SCN5A* (LQT3).[6](#jah33422-bib-0006){ref-type="ref"}, [7](#jah33422-bib-0007){ref-type="ref"} Penetrance is incomplete, and expression is variable within families; these factors complicate both interpretation of pathogenicity of sequence variants in LQTS genes and genetic counseling.[8](#jah33422-bib-0008){ref-type="ref"}

Most molecular genetic studies of LQTS have been conducted in cohorts clinically diagnosed with LQTS or ascertained through cascade screening of relatives for a specific causative variant, and 80% of families meeting clinical diagnostic criteria have detectable pathogenic or likely pathogenic sequence variants in the 17 known LQTS genes.[9](#jah33422-bib-0009){ref-type="ref"}

Current guidelines recommend genetic testing of asymptomatic patients if repetitive ECGs show a QTc ≥480 ms (European Society of Cardiology guidelines[2](#jah33422-bib-0002){ref-type="ref"}) or a QTc \>500 ms (Heart Rhythm Society/European Heart Rhythm Association Expert Consensus Statement[7](#jah33422-bib-0007){ref-type="ref"}) in the absence of secondary causes that may prolong the QT interval. An LQTS risk score (Schwartz) \>3 is also considered diagnostic.[2](#jah33422-bib-0002){ref-type="ref"}, [7](#jah33422-bib-0007){ref-type="ref"}, [10](#jah33422-bib-0010){ref-type="ref"} In accordance with current clinical guidelines for LQTS, genetic analyses have often been limited to the 3 main LQTS genes. The prevalence and spectrum of pathogenic and likely pathogenic sequence variants in the remaining LQTS genes are less well documented.

The aim of the present study was to estimate the prevalence of pathogenic and likely pathogenic sequence variants in patients who had at least 1 ECG with a QTc ≥500 ms admitted to a community hospital. Targeted sequencing was used to analyze all 17 known LQTS genes. We further wanted to determine if these patients fulfilled the clinical criteria for LQTS, according to current guidelines.

Methods {#jah33422-sec-0009}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Population and Selection of ECGs {#jah33422-sec-0010}
--------------------------------------

The patients in this study have previously been described (Figure [1](#jah33422-fig-0001){ref-type="fig"}).[11](#jah33422-bib-0011){ref-type="ref"} Briefly, the ECG database at Telemark Hospital Trust contained 225 117 ECGs from 63 286 unique patients collected throughout a period of 11 years (January 2004--December 2014). The ECG database was searched with the following criteria: QTc (Bazett\'s formula) ≥500 ms, QRS width ≤120 ms, age ≥15 years, heart rate (beats per minute) \>30 and ≤100 (because of the limitations of Bazett\'s formula), no acute ST‐segment--elevation infarction, and no atrial fibrillation or atrial flutter. All ECGs with a QTc ≥500 ms were manually reviewed, and a total of 1531 patients with at least 1 ECG with a QTc ≥500 ms were included in the previous study. These patients' first ECG with a QTc ≥500 ms is further referred to as "ECG 1."

![Flow chart of the inclusion process. QTc indicates corrected QT interval.](JAH3-7-e009706-g001){#jah33422-fig-0001}

The QT interval was measured manually in the lead showing the longest QT interval as the mean of 3 consecutive beats. We determined the end of the T wave by the tangent method, and U waves were not included if distinct from the T wave.[11](#jah33422-bib-0011){ref-type="ref"}, [12](#jah33422-bib-0012){ref-type="ref"} The average heart rate over the entire recording was used if the rhythm was regular. ECGs with frequent premature ventricular beats or short runs of supraventricular tachycardia were excluded.[11](#jah33422-bib-0011){ref-type="ref"} The QTc was calculated according to Bazett\'s formula.

At the time of inclusion in the present study (2015), 766 patients were alive, but 33 of these were excluded because of severe health problems, such as advanced dementia. A total of 733 patients were invited to participate in the study, and those who consented delivered blood for genetic testing and had a new ECG. This ECG is referred to as "ECG 2."

Clinical Data {#jah33422-sec-0011}
-------------

Clinical data, including whether the QT prolongation were acknowledged by the clinician, were obtained from the medical records at time of ECG 1, and pro‐QTc risk score was calculated for each patient.[12](#jah33422-bib-0012){ref-type="ref"} QT‐prolonging conditions included in the pro‐QTc score are listed in Table [1](#jah33422-tbl-0001){ref-type="table"}. QT‐prolonging medication was defined as any medication on the Arizona CredibleMeds QTdrugs lists.[13](#jah33422-bib-0013){ref-type="ref"} Hypomagnesemia was defined as serum magnesium ≤0.71 mmol/L, and hypokalemia was defined as serum potassium ≤3.6 mmol/L. Hypocalcemia was defined as corrected serum calcium ≤2.17 mmol/L or ionized serum calcium ≤1.18 mmol/L.

###### 

Medical Conditions and Factors Known to Prolong QTc at the Time of ECG 1 and ECG 2 for 31 Patients With Pathogenic or Likely Pathogenic Variants and 41 Patients With VUS

  QT‐Prolonging Medical Conditions                                                        Pathogenic or Likely Pathogenic Variants (n=31)   VUS (n=41)             
  --------------------------------------------------------------------------------------- ------------------------------------------------- ------------ --------- ---------
  Acute coronary syndrome within 7 d                                                      1 (3)                                             0 (0)        9 (22)    0 (0)
  Anorexia or starvation                                                                  0 (0)                                             0 (0)        0 (0)     0 (0)
  Heart rate \<45 bpm                                                                     0 (0)                                             0 (0)        0 (0)     0 (0)
  Diabetes mellitus 1 and 2                                                               4 (13)                                            4 (13)       8 (20)    8 (20)
  Ejection fraction \<40%                                                                 0 (0)                                             0 (0)        7 (17)    1 (2)
  Female sex                                                                              20 (65)                                           20 (65)      21 (51)   21 (51)
  Hypertrophic cardiomyopathy                                                             0 (0)                                             0 (0)        0 (0)     0 (0)
  Hypoglycemia (in the absence of diabetes mellitus)                                      0 (0)                                             0 (0)        0 (0)     0 (0)
  Intoxication with QT‐prolonging drugs                                                   0 (0)                                             0 (0)        2 (5)     0 (0)
  Known genetic LQTS                                                                      1 (3)                                             1 (3)        0 (0)     0 (0)
  Pheochromocytoma                                                                        0 (0)                                             0 (0)        0 (0)     0 (0)
  Renal dialysis                                                                          0 (0)                                             0 (0)        1 (2)     1 (2)
  Status \<7 d after AF conversion                                                        1 (3)                                             0 (0)        1 (2)     0 (0)
  Status \<24 h after cardiac arrest                                                      0 (0)                                             0 (0)        1 (2)     0 (0)
  Status \<24 h after syncope or seizure                                                  1 (3)                                             0 (0)        4 (10)    0 (0)
  Status \<7 d after stroke, subarachnoid hemorrhage, or head trauma                      1 (3)                                             0 (0)        1 (2)     0 (0)
  Serum electrolyte disturbances                                                          3 (10)                                            1 (3)        17 (41)   0 (0)
  Drugs with known risk of TdP[a](#jah33422-note-0003){ref-type="fn"}                     4 (13)                                            3 (10)       9 (22)    9 (22)
  Drugs with possible risk of TdP[a](#jah33422-note-0003){ref-type="fn"}                  2 (6)                                             1 (3)        4 (10)    8 (20)
  Drugs with conditional risk of TdP[a](#jah33422-note-0003){ref-type="fn"}               11 (35)                                           10 (32)      18 (44)   19 (46)
  Drugs with special risk for patients with LQTS[a](#jah33422-note-0003){ref-type="fn"}   2 (6)                                             1 (3)        6 (15)    2 (5)

Data are given as number (percentage) of patients. AF indicates atrial fibrillation; bpm, beats per minute; LQTS, long‐QT syndrome; QTc, corrected QT interval; TdP, torsade de pointes ventricular tachycardia; VUS, variants of uncertain significance.

The QT‐prolonging drug categories are according to AZCERT, Inc.[13](#jah33422-bib-0013){ref-type="ref"}

QT Interval and LQTS Risk Score (Schwartz) {#jah33422-sec-0012}
------------------------------------------

It was noted whether the patients with a pathogenic or likely pathogenic variant and the patients with variants of uncertain significance (VUS) met the criteria for a clinical diagnosis of LQTS on the basis of current guidelines.[2](#jah33422-bib-0002){ref-type="ref"}, [7](#jah33422-bib-0007){ref-type="ref"} The LQTS risk score (Schwartz) was based on QTc from ECG 2 because it was least affected by environmental factors.[2](#jah33422-bib-0002){ref-type="ref"}, [10](#jah33422-bib-0010){ref-type="ref"} The difference in QTc between ECG 1 and ECG 2 was also calculated.

DNA Sequencing {#jah33422-sec-0013}
--------------

The 17 genes in which mutations are known to cause monogenic LQTS were sequenced: *AKAP9* ([NM_005751.4](NM_005751.4)), *ANK2* ([NM_1148.4](NM_1148.4)), *CACNA1C* ([NM_000719.6](NM_000719.6)), *CALM1* ([NM_006888.4](NM_006888.4)), *CALM2* ([NM_001743.4](NM_001743.4)), *CALM3* ([NM_005184.2](NM_005184.2)), *CAV3* ([NM_033337.2](NM_033337.2)), *KCNE1* ([NM_000219.5](NM_000219.5)), *KCNE2* ([NM_172201.1](NM_172201.1)), *KCNH2* ([NM_000238.3](NM_000238.3)), *KCNJ2* ([NM_000891.2](NM_000891.2)), *KCNJ5* ([NM_000890.3](NM_000890.3)), *KCNQ1* ([NM_000218.2](NM_000218.2)), *SCN4B* ([NM_174934.3](NM_174934.3)), *SCN5A* ([NM_198056.2](NM_198056.2)), *SNTA1* ([NM_003098.2](NM_003098.2)), and *TRDN* ([NM_006073.3](NM_006073.3)). The patients were not referred to testing in a clinical setting, but were included in a research project based solely on prolonged QTc.[11](#jah33422-bib-0011){ref-type="ref"} Further details on DNA sequencing, bioinformatics, and RNA analyses are found in Data [S1](#jah33422-sup-0001){ref-type="supplementary-material"}.

Variant Interpretation {#jah33422-sec-0014}
----------------------

An alternative allele frequency cutoff of 0.1% from the Exome Aggregation Consortium database (populations: all or non‐Finnish Europeans) was used for filtering variants (Figure [2](#jah33422-fig-0002){ref-type="fig"}). Additional databases of allele frequencies, such as gnomAD,[14](#jah33422-bib-0014){ref-type="ref"} SweGen,[15](#jah33422-bib-0015){ref-type="ref"} 2000 Danes,[16](#jah33422-bib-0016){ref-type="ref"} and the in‐house Telemark database with ≈1000 exomes, were consulted when manually reviewing the variants that remained after filtering. Sequence variants that were synonymous (predicting no change in amino acids), intronic (outside splice sites), or in untranslated regions were discarded, unless they had previously been reported as pathogenic or likely pathogenic. Genes and variants that remained after filtering were manually reviewed in the light of available clinical and biological data to evaluate causality. The key tools used for this were Alamut Visual decision‐support software (Interactive Biosoftware), Human Gene Mutation Database,[5](#jah33422-bib-0005){ref-type="ref"} and ClinVar.[17](#jah33422-bib-0017){ref-type="ref"}

![Flow chart of filtering and evaluation of sequence variants. Bp indicates base pair; ExAC, Exome Aggregation Consortium; LQT, long QT; QC, quality control.](JAH3-7-e009706-g002){#jah33422-fig-0002}

Sequence variants were divided into 5 classes: class 5, pathogenic; class 4, likely pathogenic; class 3, uncertain significance; class 2, likely benign; and class 1, benign. Classification was based on guidelines from the Association for Clinical Genetic Science and the American College of Medical Genetics and Genomics.[18](#jah33422-bib-0018){ref-type="ref"} Previously reported pathogenic and likely pathogenic variants were not accepted as pathogenic without scrutinizing newly available evidence, such as allele frequencies and in vitro studies.

Statistical Analysis {#jah33422-sec-0015}
--------------------

Continuous data were described by mean±SD or median (range) and compared using the unpaired Student *t* test or independent‐samples Mann‐Whitney *U* test, as appropriate. Categorical data were described as proportions and analyzed by the χ^2^ test (SPSS, version 23.0; IBM, Armonk, NY). A 2‐sided *P*\<0.05 was considered statistically significant.

Ethics {#jah33422-sec-0016}
------

The study complies with the Declaration of Helsinki. The Norwegian Regional Committee for Medical and Health Research Ethics has approved the study (2013/1090), and informed consent was obtained from all patients. Genetic counseling was offered to all patients with pathogenic or likely pathogenic mutations. Patients with a pathogenic or likely pathogenic variant were assigned an LQTS diagnosis in an inherited disease clinic.

Results {#jah33422-sec-0017}
=======

Characteristics of Study Population at Time of First ECG With QTc ≥500 ms (ECG 1) {#jah33422-sec-0018}
---------------------------------------------------------------------------------

Demographics for the 475 (65%) of 733 patients who participated in the study are shown in Table [2](#jah33422-tbl-0002){ref-type="table"}. They underwent genetic testing and were on average 3 years younger than those who declined (63±14 versus 66±16 years; *P*=0.01). There were no significant differences in QTc, sex, hypokalemia, number of QT‐prolonging conditions, number of QT‐prolonging drugs, or pro‐QTc score between study participants and nonparticipants at the time of ECG 1 (Table [2](#jah33422-tbl-0002){ref-type="table"}).

###### 

Demographics of 733 Invited Patients at the Time of the First ECG With QTc ≥500 ms ("ECG 1")

  Demographics                                                             Total (n=733)    Participants (n=475)   Nonparticipants (n=258)   *P* Value
  ------------------------------------------------------------------------ ---------------- ---------------------- ------------------------- -----------
  Age, y                                                                   64±15            63±14                  66±16                     0.01
  Female sex                                                               448 (61)         294 (62)               154 (60)                  0.58
  Heart rate, bpm                                                          78 (39--100)     77 (39--100)           81 (48--100)              \<0.01
  QRS duration, ms                                                         94±12            93±12                  94±12                     0.32
  QTc, ms                                                                  512 (500--669)   512 (500--669)         515 (500--634)            0.17
  Hypokalemia                                                              200/683 (29)     124/441 (30)           76/242 (31)               0.60
  No. of QT‐prolonging drugs                                               1 (0--5)         1 (0--5)               1 (0--5)                  0.34
  No. of QT‐prolonging conditions[a](#jah33422-note-0005){ref-type="fn"}   1 (0--4)         1 (0--4)               1 (0--3)                  0.29
  Pro‐QTc score                                                            2.7±1.5          2.7±1.6                2.7±1.5                   0.95

Data are given as mean±SD, number/total (percentage), or median (range). Bpm indicates beats per minute; QTc, corrected QT interval.

Female sex, electrolyte disturbances, and medication not included.

A pathogenic or likely pathogenic genetic variant was identified in 31 (6.5%) of 475 patients (Table [3](#jah33422-tbl-0003){ref-type="table"}). The criteria applied for classification of genetic variants are shown in Table [4](#jah33422-tbl-0004){ref-type="table"}. These patients had a lower pro‐QTc score than those without pathogenic or likely pathogenic variants (1.7±1.0 versus 2.8±1.6; *P*\<0.001) (Table [5](#jah33422-tbl-0005){ref-type="table"}). Of the 31 patients with a pathogenic or likely pathogenic variant, 12 (39%) had an additional nongenetic explanation for QTc prolongation at the time of ECG 1 (Table [1](#jah33422-tbl-0001){ref-type="table"}). The median serum potassium level was 3.5 mmol/L (range, 3.4--3.6 mmol/L) among those with hypokalemia. The sole acute coronary syndrome was minor, without any other ECG changes than the QTc prolongation. Three patients with pathogenic or likely pathogenic variants used potent QT‐prolonging antiarrhythmic drugs (Table [S1](#jah33422-sup-0001){ref-type="supplementary-material"}).

###### 

Patients With a Pathogenic or Likely Pathogenic Variant

  No.   Gene      cDNA Change      Protein Change        Age at ECG 1, y   Sex      QTc at ECG 1, ms   QTc at ECG 2, ms   Family History   Syncope
  ----- --------- ---------------- --------------------- ----------------- -------- ------------------ ------------------ ---------------- ---------
  1     *KCNH2*   c.157G\>A        p.(Gly53Ser)          56                Male     535                496                No               Yes
  2     *KCNH2*   c.2257G\>T       p.(Ala753Ser)         15                Male     520                450                No               Yes
  3     *KCNH2*   c.2682_2685dup   p.(Asp896Hisfs\*25)   53                Male     513                565                No               No
  4     *KCNH2*   c.2775dup        p.(Pro926Alafs\*14)   58                Female   517                511                No               No
  5     *KCNQ1*   c.573_577del     p.(Arg192Cysfs\*91)   62                Male     504                492                No               No
  6     *KCNQ1*   c.1588C\>T       p.(Gln530\*)          39                Female   508                508                No               Yes
  7     *KCNQ1*   c.1588C\>T       p.(Gln530\*)          39                Male     509                413                No               No
  8     *KCNQ1*   c.1588C\>T       p.(Gln530\*)          43                Female   501                481                No               No
  9     *KCNQ1*   c.1588C\>T       p.(Gln530\*)          45                Female   520                458                No               Yes
  10    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          51                Male     551                477                No               No
  11    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          57                Female   504                473                No               No
  12    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          60                Female   504                469                No               No
  13    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          62                Female   510                467                Yes              Yes
  14    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          62                Female   543                459                No               No
  15    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          64                Female   502                470                No               No
  16    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          66                Male     501                486                No               No
  17    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          68                Female   538                482                No               No
  18    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          70                Male     508                495                No               No
  19    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          70                Male     503                457                No               No
  20    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          73                Male     577                NA                 No               No
  21    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          77                Female   520                484                No               No
  22    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          79                Female   506                474                No               No
  23    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          81                Female   506                499                No               No
  24    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          83                Female   515                459                No               No
  25    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          86                Female   516                475                No               No
  26    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          86                Female   508                474                No               No
  27    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          87                Female   532                520                No               Yes
  28    *KCNQ1*   c.1588C\>T       p.(Gln530\*)          88                Female   511                462                Yes              No
  29    *KCNQ1*   c.1591‐1G\>A     p.?                   56                Female   502                496                No               No
  30    *KCNQ1*   c.1760C\>T       p.(Thr587Met)         38                Female   504                493                Yes              No
  31    *SCN5A*   c.4931G\>A       p.(Arg1644His)        58                Male     513                481                No               Yes

NA indicates not available; QTc, corrected QT interval.

###### 

ACMG Criteria Used for Classification of Pathogenic and Likely Pathogenic Variants

  Gene      cDNA Change      Protein Change        ACMG/AMP Criteria                                                  Classification
  --------- ---------------- --------------------- ------------------------------------------------------------------ -------------------
  *KCNH2*   c.2775dup        p.(Pro926Alafs\*14)   PVS1, PS3, PM2                                                     Pathogenic
  *KCNH2*   c.2682_2685dup   p.(Asp896Hisfs\*25)   PVS1, PM2, PP5                                                     Pathogenic
  *KCNH2*   c.2257G\>T       p.(Ala753Ser)         PM1, PM2, PP2, PP3, PP5                                            Likely pathogenic
  *KCNH2*   c.157G\>A        p.(Gly53Ser)          PM1, PM2, PM5‐S[a](#jah33422-note-0008){ref-type="fn"}, PP2, PP5   Pathogenic
  *KCNQ1*   c.573_577del     p.(Arg192Cysfs\*91)   PVS1, PP1, PP5                                                     Pathogenic
  *KCNQ1*   c.1588C\>T       p.(Gln530\*)          PVS1, PS4, PP1                                                     Pathogenic
  *KCNQ1*   c.1591‐1G\>A     p.?                   PVS1, PS3, PM2                                                     Pathogenic
  *KCNQ1*   c.1760C\>T       p.(Thr587Met)         PS1, PS3, PM1, PM2, PP5                                            Pathogenic
  *SCN5A*   c.4931G\>A       p.(Arg1644His)        PS1, PS3, PM2, PP3                                                 Pathogenic

ACMG indicates American College of Medical Genetics and Genomics; AMP, Association for Molecular Pathology; PM, pathogenic moderate; PP, pathogenic supporting; PS, pathogenic strong; PVS, pathogenic very strong.

PM5 assigned strong evidence of pathogenicity because both Gly53Asp and Gly53Arg previously have been reported as pathogenic and both were trafficking deficient.

###### 

Demographics of 475 Genetically Tested Patients at the Time of the First ECG With QTc ≥500 ms ("ECG 1")

  Demographics                                                             Total (n=475)    Pathogenic or Likely Pathogenic Variant (n=31)   VUS and Negative Genetic Test Result (n=444)   *P* Value
  ------------------------------------------------------------------------ ---------------- ------------------------------------------------ ---------------------------------------------- -----------
  Age, y                                                                   63±14            63±17                                            63±14                                          0.86
  Female sex                                                               294 (62)         20 (65)                                          274 (62)                                       0.85
  Heart rate, bpm                                                          77 (39--100)     66 (41--97)                                      77 (39--100)                                   \<0.01
  QRS duration, ms                                                         93±12            88±10                                            94±12                                          \<0.01
  QTc, ms                                                                  512 (500--669)   511 (501--577)                                   512 (500--669)                                 0.50
  Hypokalemia                                                              124/441 (28)     3/22 (14)                                        121/419 (30)                                   \<0.001
  No. of QT‐prolonging drugs                                               1 (0--5)         0 (0--2)                                         1 (0--5)                                       0.071
  No. of QT‐prolonging conditions[a](#jah33422-note-0010){ref-type="fn"}   1 (0--4)         0 (0--1)                                         1 (0--4)                                       0.001
  Pro‐QTc score                                                            2.7±1.6          1.7±1.0                                          2.8±1.6                                        \<0.001

Data are given as mean±SD, number/total (percentage), or median (range). Bpm indicates beats per minute; QTc, corrected QT interval; VUS, variants of uncertain significance.

Female sex, electrolyte disturbances, and medication not included.

Among the patients without pathogenic or likely pathogenic variants, 75 (74%) of the 101 patients with acute coronary syndrome had ischemic ECG changes. The median serum potassium level was 3.4 mmol/L (range, 1.9--3.6 mmol/L) among those with hypokalemia.

A genetic VUS was identified in 41 (8.6%) of 475 patients (Table [S2](#jah33422-sup-0001){ref-type="supplementary-material"}). There were no significant differences in QTc, sex, hypokalemia, number of QT‐prolonging conditions, number of QT‐prolonging drugs, or pro‐QTc score between these patients and patients with negative genetic test results (Table [S3](#jah33422-sup-0001){ref-type="supplementary-material"}). All of the patients carrying a VUS had a plausible nongenetic explanation for QTc prolongation at the time of ECG 1 (Table [1](#jah33422-tbl-0001){ref-type="table"}, Table [S4](#jah33422-sup-0001){ref-type="supplementary-material"}).

Awareness of QT Prolongation by Healthcare Provider {#jah33422-sec-0019}
---------------------------------------------------

QTc prolongation was acknowledged in the medical records in 7 (23%) of the 31 patients with a pathogenic or likely pathogenic variant at the time of ECG 1. Only 1 of those had been offered a follow‐up visit and was found to have a QTc of 472 ms after discontinuation of QT‐prolonging medication. QT prolongation was acknowledged in the medical records in 59 (13%) of the 444 patients without a pathogenic or likely pathogenic variant.

QT Interval and LQTS Risk Score (Schwartz) {#jah33422-sec-0020}
------------------------------------------

Among the patients with a pathogenic or likely pathogenic variant, the median QTc in ECG 1 was 511 ms (range, 501--577 ms) and the median QTc in ECG 2 was 479 ms (range, 413--565 ms) (Table [3](#jah33422-tbl-0003){ref-type="table"}). One patient missed ECG 2. The median difference between the QTc in ECG 1 and ECG 2 was −33 ms (range, −96 to 52 ms) (Figure [3](#jah33422-fig-0003){ref-type="fig"}). Of 30 patients, 4 (13%) had a QTc ≥500 ms and 15 (50%) had a QTc \<480 ms on ECG 2 (Figure [4](#jah33422-fig-0004){ref-type="fig"}). Only 1 of the patients with a pathogenic or likely pathogenic variant had a longer QTc at the time of ECG 2 compared with ECG 1.

![Corrected QT interval at the time of ECG 1 and ECG 2 among 31 patients with pathogenic or likely pathogenic variants and 41 patients with variants of uncertain significance.](JAH3-7-e009706-g003){#jah33422-fig-0003}

![Bar chart showing the corrected QT interval (QTc) distribution at the time of ECG 2 among 30 patients with pathogenic or likely pathogenic variants (red) and 40 patients with variants of uncertain significance (blue).](JAH3-7-e009706-g004){#jah33422-fig-0004}

Of the 31 patients with a pathogenic or likely pathogenic variant, 6 (19%) fulfilled the criteria for a clinical diagnosis of LQTS on the basis of LQTS risk score (Schwartz). One patient had a family history of sudden death in a first‐degree relative with congenital deafness who died at the age of 6 years. Another patient had a known family history of LQTS. Furthermore, 1 patient had a previously diagnosed LQTS. From the age of 6 years, 1 patient had experienced fainting spells, previously thought to be of epileptic origin, but now considered symptoms of LQTS. No patients had any documented episodes of torsade de pointes ventricular tachycardia or cardiac arrest, but 6 patients had previously had a syncope that could have been related to LQTS.

For the patients with a VUS, the median QTc in ECG 1 was 510 ms (range, 500--639 ms) and the median QTc in ECG 2 was 449 ms (range, 377--498 ms). One patient missed ECG 2. The median difference between the QTc in ECG 1 and ECG 2 was −73 ms (range, −5 to −228 ms) (Figure [3](#jah33422-fig-0003){ref-type="fig"}). None of the patients carrying a VUS had a QTc ≥500 ms, and 35 (88%) of 40 patients had a QTc of \<480 ms on ECG 2 (Figure [4](#jah33422-fig-0004){ref-type="fig"}). None of the patients with VUS had an LQTS risk score (Schwartz) \>3. None had a family history of sudden death in a first‐degree relative. One patient with a VUS (c.5962A\>C p.\[Met1988Leu\] in ANK2) had a syncope that could have been related to LQTS, had documented polymorphic ventricular tachycardia, and had an implantable cardioverter‐defibrillator implanted.

Patients with a pathogenic or likely pathogenic variant had a higher median QTc in ECG 2 than the patients with VUS (479 versus 449 ms; *P*\<0.001).

Genetic Analyses {#jah33422-sec-0021}
----------------

A total of 670 sequence variants were detected in the 17 known LQTS genes. Of these, 69 were coding or splice site variants with a minor allele frequency \<0.1% in the Exome Aggregation Consortium database (Figure [2](#jah33422-fig-0002){ref-type="fig"}). On average, the patients harbored 0.26 such rare coding variants. All pathogenic or likely pathogenic variants were heterozygous. The previously reported variant *KCNQ1* c.1588C\>T p.(Gln530\*) was present in 23 patients. The other 8 variants were all detected in single cases. Patients heterozygous for p.(Gln530\*) were older than the other patients with a pathogenic or likely pathogenic variant (67±16 versus 50±16 years; *P*=0.01) and more likely to be women (74% versus 38%; *P*=0.08) (Table [S5](#jah33422-sup-0001){ref-type="supplementary-material"}). By excluding patients with the Gln530\* variant, the 8 patients with pathogenic or likely pathogenic variants other than *KCNQ1* c.1588C\>T p.(Gln530\*) were younger than the patients with negative genetic test results (50±16 versus 63±14 years; *P*\<0.01).

Two novel pathogenic null variants were detected. *KCNH2* c.2682_2685dup p.(Asp896Hisfs\*25) is located in the 3′ end of exon 11 and within a few base pairs reach of 3 other frameshift variants previously reported in patients with LQTS.[19](#jah33422-bib-0019){ref-type="ref"}, [20](#jah33422-bib-0020){ref-type="ref"}, [21](#jah33422-bib-0021){ref-type="ref"} *KCNQ1* c.1591‐1G\>A p.(?) disrupts normal pre‐mRNA splicing (Figure [S1](#jah33422-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah33422-sec-0022}
==========

In the present study, a genetic diagnosis was obtained in 31 (6.5%) of 475 patients with at least 1 ECG with a QTc ≥500 ms. This illustrates that a QTc ≥500 ms in at least 1 ECG recording may greatly increase the likelihood of pathogenic or likely pathogenic variants in LQTS genes in hospitalized patients compared with the general population. This is a 130‐fold increase relative to the estimated population prevalence of 1:2000.[1](#jah33422-bib-0001){ref-type="ref"}

Current guidelines from the European Society of Cardiology recommend clinical diagnosis and genetic testing in an asymptomatic individual if repetitive ECGs show a QTc ≥480 ms. An LQTS risk score (Schwartz) \>3 is also clinically diagnostic.[2](#jah33422-bib-0002){ref-type="ref"} Genetic testing is usually reserved for patients with persistent QTc prolongation after withdrawal or resolution of the QT‐prolonging factors. We, therefore, included ECG 2 after QT‐prolonging factors had been recognized and modified when appropriate and the patients with an acute illness had recovered. If European Society of Cardiology guidelines had been followed, 47% of the patients with a pathogenic or likely pathogenic variant in the present study would probably not have been considered for the diagnosis. The Heart Rhythm Society/European Heart Rhythm Association Expert Consensus Statement recommends cutoff on repetitive ECGs to QTc \>500 ms, which would have failed to diagnose 73% of the patients with a pathogenic or likely pathogenic variant in the present study.[7](#jah33422-bib-0007){ref-type="ref"}

The awareness of QT prolongation and the possibility of LQTS was low. At Telemark Hospital Trust, the physician ordering the ECG is responsible for the interpretation. At the time of the present study, the QTc duration was indicated on the ECG, but without automated description or flagging of the QT prolongation. QT alert systems have been described previously and could increase awareness of QT prolongation.[12](#jah33422-bib-0012){ref-type="ref"}

The previously reported *KCNQ1* c.1588C\>T p.(Gln530\*) was identified in 23 of 31 patients with a pathogenic or likely pathogenic variant. Thus, this founder mutation inflates the prevalence of LQTS in Telemark. The Gln530\* carriers were significantly older than the other patients with pathogenic or likely pathogenic variants, which could question this variant\'s effect on QTc interval and mortality. Several other variants previously reported to cause LQTS have recently been proved to have no effect on QTc, syncope, or overall mortality.[22](#jah33422-bib-0022){ref-type="ref"} This illustrates the need for reevaluation before accepting previous claims of pathogenicity. Gln530\* has previously been reported as the most prevalent pathogenic KCNQ1 variant in Norway,[6](#jah33422-bib-0006){ref-type="ref"} and it is most common in Telemark\'s neighbor district, Agder. It has consistently been reported as pathogenic in several populations.[17](#jah33422-bib-0017){ref-type="ref"} In the gnomAD database, Gln530\* is present in 7 of 55 818 non‐Finnish European individuals, but absent from all other populations. The variant is also absent from SweGen, 2000 Danes, 1000 genomes Norway, and the Telemark database, which together contain 8000 alleles.[15](#jah33422-bib-0015){ref-type="ref"}, [16](#jah33422-bib-0016){ref-type="ref"}, [23](#jah33422-bib-0023){ref-type="ref"} This supports that the variant is associated with a significant increase in QTc and with an increased risk of cardiac events, although this risk is reported to be lower than for *KCNQ1* missense variants.[24](#jah33422-bib-0024){ref-type="ref"}

Most studies on the risk of life‐threatening outcomes in LQTS have been performed in children and young adults, in contrast to the population in our study. Risk of adverse outcome has been assumed to be low in patients \>40 years of age. However, in a previous study from the International Long QT Syndrome Registry, the risk of aborted cardiac arrest, sudden cardiac death, and implantable cardioverter‐defibrillator therapy was maintained until the age of 60 years.[25](#jah33422-bib-0025){ref-type="ref"} The likelihood of serious cardiac events is increased in carriers of a pathogenic variant, even when the QTc is within the normal range.[3](#jah33422-bib-0003){ref-type="ref"} Thus, for the patients with a pathogenic or likely pathogenic variant in our population, lifestyle modifications, evaluation of drug use, and in some cases prophylactic medical treatment are indicated.

Genetic cascade testing for detected LQTS mutations is warranted by the ability to identify relatives at risk. Many at‐risk individuals are likely to be unaware of their status in light of the disorder\'s incomplete penetrance, variable expressivity, and unpredictable course.[6](#jah33422-bib-0006){ref-type="ref"}, [26](#jah33422-bib-0026){ref-type="ref"} The risk of life‐threatening cardiac events is highest in young adolescence, and identification of a pathogenic variant in an LQTS gene has the potential to prevent life‐threatening cardiac events in offspring or siblings.[7](#jah33422-bib-0007){ref-type="ref"}, [27](#jah33422-bib-0027){ref-type="ref"}

More patients with a pathogenic or likely pathogenic variant had a diagnostic Schwartz score, no clear QT‐prolonging factor, and persistent QT prolongation on ECG 2 compared with the patients with a VUS. Furthermore, many of the patients with a pathogenic or likely pathogenic variant had QT prolongation exceeding the values that one may expect from a specific QT‐prolonging factor, favoring these patients when considering patients for genetic testing. A role for common variants on QT interval and arrhythmia has been demonstrated, but they still have limited clinical utility and their contribution in this cohort has not been analyzed.[28](#jah33422-bib-0028){ref-type="ref"}, [29](#jah33422-bib-0029){ref-type="ref"}

Of the 17 genes tested, pathogenic or likely pathogenic variants were detected only in the 3 major genes *KCNQ1*,*KCNH2*, and *SCN5A*. In contrast, 7 genes contained at least 1 VUS, and only 16 of 47 VUS were identified in the 3 major genes. Five patients carried 2 VUS each. One of these patients was asymptomatic but had consistently QTc \>480 ms in \>10 ECGs, and another patient had QTc ≥497 ms in 4 ECGs. It could be speculated that the coexistence of \>1 VUS could increase QTc, because additive effects have been suggested by others.[30](#jah33422-bib-0030){ref-type="ref"}, [31](#jah33422-bib-0031){ref-type="ref"} However, the clinical characteristics of the 41 patients with VUS are comparable to the mutation‐negative group. This supports the notion that VUS are of limited clinical importance. Whether a VUS represents a benign variant, a proarrhythmic variant requiring secondary provocation, or a truly pathogenic variant remains to be determined. Until then, they should not be used for clinical decisions.

Study Limitations {#jah33422-sec-0023}
-----------------

All patients were recruited from Telemark County in Norway, which has 173 000 inhabitants who are relatively homogeneous from a genetic perspective. The mutation spectrum would thus likely be different in other populations. The Gln530\* variant inflates the prevalence of LQTS in Telemark, and the prevalence of LQTS may be different in other populations.

Only patients still alive at the time of inclusion were included. The mutation spectrum and prevalence of pathogenic or likely pathogenic variants may be different in the deceased individuals. It is possible that patients with a history of cardiac disease (themselves or relatives) are more prone to accept genetic testing.

Only the 17 known LQTS genes have been sequenced, and not all genetic defects in these genes will be detected by next‐generation sequencing. Most intronic variants and deletions/duplications larger than ≈40 base pairs escape detection. Interpretation of the pathogenicity of genetic variation is based on current genetic and medical knowledge and is likely to change over time.

The pro‐QTc score was developed to predict mortality in hospitalized patients with QT prolongation. In the present study, the pro‐QTc score was used to assess the number of QT‐prolonging factors. The CredibleMeds QTdrugs lists were accessed in 2015, and the pro‐QTc score, therefore, does not include the most recent drugs added to the lists. Automated T‐wave morphological analyses were not performed in the present study. Future studies should assess T‐wave morphological characteristics in patients with a prolonged QT interval.

Bazett\'s formula overestimates QTc at high heart rates, but there were no significant differences between the groups at the time of ECG 1 using QTc Fredericia or QTc Framingham (Table [S6](#jah33422-sup-0001){ref-type="supplementary-material"}).

Conclusion {#jah33422-sec-0024}
==========

We detected a molecular genetic diagnosis of LQTS in 31 (6.5%) of 475 patients with at least 1 ECG with a QTc ≥500 ms in a community hospital. Compared with the general population, hospitalized patients with a QTc ≥500 ms in at least 1 ECG recording had an increased likelihood for pathogenic and likely pathogenic variants in LQTS genes. If European Society of Cardiology guidelines had been followed, 47% of the patients carrying pathogenic and likely pathogenic variants in the present study would not have been diagnosed. If the Heart Rhythm Society/European Heart Rhythm Association Expert Consensus Statement had been adhered to, 73% of the patients would not have been diagnosed. We recommend increased awareness of the possibility of LQTS in patients with at least 1 ECG with a QTc ≥500 ms.
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